Proteasome inhibitors and immunomodulatory drugs have demonstrated improvements in survival and response in patients with multiple myeloma.
Many CML patients on TKI treatment report muscle complaints, but there has been little work to find out why. A new study sought to find out more about the nature of these complaints and to undercover a biological mechanism to explain them.
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Advances in treatment options for acute myeloid leukemia may replace currently accepted induction regimens as the standard of care.
Treatment with erythropoietin-stimulating agents may yield improved hematopoietic responses and reduce the need for red blood cell transfusions.